Head to Head: CRISPR Therapeutics AG (CRSP)’s and Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR)

Reviewing CRISPR Therapeutics AG (CRSP)’s and Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR)’s results

Both CRISPR Therapeutics AG (NASDAQ:CRSP) and Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership.

READ MORE …

Head to Head: Fate Therapeutics (NASDAQ:FATE) versus Genetic Technologies (GENE)

Head to Head Contrast: Fate Therapeutics (NASDAQ:FATE) and Genetic Technologies (GENE)

Head to Head: Fate Therapeutics (NASDAQ:FATE) versus Genetic Technologies (GENE)

Genetic Technologies (NASDAQ:GENE) and Fate Therapeutics (NASDAQ:FATE) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership.


READ MORE …

Bloomberg covers important investor interest in gene editing therapyBloomberg covers important investor interest in gene editing therapy

Bloomberg covers important investor interest in gene editing therapy

Biotech Investors Zero In on Gene Therapy as Next Big Frontier

(Bloomberg) -- Biotech investors are bullish on the market for gene therapies, even though actual sales of a few existing drugs have so far failed to impress some Wall Street analysts. Fund managers and venture capitalists discussed their outlook for the technology in interviews in Boston, where investors gathered for the Cowen health-care conference. Investor interest in gene-therapy stocks is high, as investing has paid off this year. Roche Holding AG and Biogen Inc. recently snapped up a pair of drug developers, boosting speculation of more deals. Also, U.S. regulators say they expect to approve 10 to 20 new medicines by 2025, while insurers grapple with treatment costs that can run into the hundreds of thousands of dollars.

READ MORE …

Head to Head: CRISPR Therapeutics AG (CRSP)’s versus Pain Therapeutics Inc. (NASDAQ:PTIE)

Head to Head: CRISPR Therapeutics AG (CRSP)’s versus Pain Therapeutics Inc. (NASDAQ:PTIE)

CRISPR Therapeutics AG (NASDAQ:CRSP) and Pain Therapeutics Inc. (NASDAQ:PTIE) compete with each other in the Biotechnology sector. We will analyze and contrast their risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation.


READ MORE …

Head to Head: PerkinElmer Inc. (NYSE:PKI) and Cancer Genetics Inc. (NASDAQ:CGIX)

Head to Head: PerkinElmer Inc. (NYSE:PKI) and Cancer Genetics Inc. (NASDAQ:CGIX)

We will be comparing the differences between PerkinElmer Inc. (NYSE:PKI) and Cancer Genetics Inc. (NASDAQ:CGIX) as far as analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation are concerned. The two businesses are rivals in the Medical Laboratories & Research industry.


READ MORE …

Head to Head: Seattle Genetics Inc. (SGEN) and Benitec Biopharma Limited (NASDAQ:BNTC)

Head to Head: Seattle Genetics Inc. (SGEN) and Benitec Biopharma Limited (NASDAQ:BNTC)

We will be comparing the differences between Seattle Genetics Inc. (NASDAQ:SGEN) and Benitec Biopharma Limited (NASDAQ:BNTC) as far as risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.


READ MORE …

Introduction to organioids

What you need to know about organoids

By Chloe Reichel

Paola Arlotta, chair of and professor in the stem cell and regenerative biology department at Harvard University, is growing brain tissue in her lab. In recent years, scientists have developed new techniques that add another level to the two-dimensional tissue culture of yore (e.g., growing cells in a single layer in a petri dish). These cells grow and divide in three dimensions, ultimately giving rise to samples of tissue that resemble the organ itself. They’re called organoids, but many news headlines have described them as if they are real, live organs.

Take these headlines for example: “Scientists grow human brains in a dish” and “Scientists brew up the creepiest batches of brain balls yet.” While science is in its infancy, the headlines don’t reflect that, taking liberties in describing what organoids are and overstating their form and function.

“You imagine a mini brain in a dish — that’s not what these things are,” Arlotta stresses. That bears repeating: They’re not mini brains; they’re not brains in a dish. They’re brain organoids, simplified replicas with some of the features of the organ they model.

READ MORE …

Cabozantinib added to the kidney cancer treatment arsenal

Cabozantinib Approval Expands Initial Treatment Options for Advanced Kidney Cancer

Cabozantinib added to the kidney cancer treatment arsenal. Genome Media.

For patients with the most common type of kidney cancer, there is now a new approved use of the targeted therapy cabozantinib (Cabometyx®). In December 2017, the Food and Drug Administration (FDA) approved use of the drug as an initial, or first-line, treatment for patients with advanced renal cell carcinoma (RCC).






READ MORE …




UK Research and Innovation awards £45 million to EMBL’s European Bioinformatics Institute (EMBL-EBI)

Funding awarded for bioinformatics infrastructure

UK Research and Innovation (UKRI) has awarded £45 million to EMBL’s European Bioinformatics Institute (EMBL-EBI), to enhance the institute’s technical and building infrastructure. The funding, which comes from the UKRI’s Strategic Priorities Fund, will support EMBL-EBI’s existing and emerging data resources, including in areas of major interest, such as genomics and bioimaging.

READ MORE …

Minimap2 makes sophisticated analysis possible on hand-held devices

The Garvan Institute brings DNA analysis capabilities to smartphones

The Garvan Institute of Medical Research has partnered with the University of NSW to take genome analysis ‘offline’ by adapting the algorithms that perform DNA analysis to require far less compute than current tools.

Minimap2 makes sophisticated analysis possible on hand-held devices. Genome Media.

Medical practitioners fighting the Ebola and Zika viruses in New Guinea and Brazil have already used small genome sequencing devices that can clip on to a smartphone, but these devices still require high-performance computer workstations or reliable internet connections to identify genes.

Devices like the Oxford Nanopore Technologies MinION can create over a terabyte of data in 48 hours, but their use still isn’t commonplace because comparing or ‘aligning’ DNA from an unknown sample to a reference database to figure out what the sample is requires around 16 GB of RAM, which is beyond the capabilities of most mid-range laptops and flagship smartphones.

For cash-strapped medical programs in developing countries or during large-scale outbreaks, that kind of processing power isn’t easy to come by at scale, and a reliable internet connection can be just as hard to find.

In a new paper released in Nature, Garvan’s Genomic Technologies lead Dr Martin Smith and his team detailed the computational method for reducing the amount of memory needed for aligning sequences from 11GB to 2GB - well within the reach of mid-range smartphones.

The researchers adapted the Minimap2 program, which aligns DNA sequencing ‘reads’ to a reference library of known genomes.


READ MORE …

Gencove expanding whole genome sequencing

Gencove raises $3M investment led by Spero Ventures to expand genome sequencing platform

Gencove expanding whole genome sequencing. Genome Media

NEW YORK, /PRNewswire/ -- Gencove, the leading low-pass genome sequencing platform, announced today a $3 million investment led by Spero Ventures. Alexandria Venture Investments and Burst Capital participated in the round, along with existing investors Third Kind Venture Capital and Version One Ventures. The funding will be used to develop new applications for agricultural markets as well as expand Gencove's commercial operations in human genetics. Shripriya Mahesh, partner at Spero, will join Gencove's board of directors.

"Genomics will be foundational to the health and well-being of humanity and the planet," said Shripriya Mahesh. "We are excited partner with Gencove in its mission to bring affordable whole genome sequencing to customers and industries that have never before been able to affordably integrate it at scale."


READ MORE …

Positive results for Epic prostate cancer testing

Blood Test Study Meets Goal, Validates Epic’s Prostate Cancer Target

Positive results for Epic prostate cancer testing. Genome Media.

Epic Sciences has commercialized a blood test that can predict how likely a patient with late-stage prostate cancer treated with hormones is likely to respond to an additional course of such therapy. Now, the San Diego-based company has additional data that it says supports use of its tests to determine when not to use hormone therapy



READ MORE …

Gene expression used for leukemia diagnostics

Gene expression patterns identify high-risk chronic lymphocytic leukemia

Gene expression used for leukemia diagnostics. Genome Media.

A 290-gene expression signature and IGHV mutation status stratified patients with chronic lymphocytic leukemia to identify those with high-risk disease who might benefit from prompt initiation of therapy, according to a study published in Frontiers in Oncology.

Although CLL treatment is typically delayed until disease progression, it is uncertain whether patients would benefit from treatment immediately following diagnosis, when they have a smaller tumor mass and are in better physical condition.


READ MORE ..

Berkeley gets another CRISPR patent

University of California granted another CRISPR patent

UC Berkeley announced Tuesday it received a patent for a single-molecule guide RNA that can be used with the Cas-9 enzyme by the gene-editing tool CRISPR in plants, bacteria and mammalian cells.

Why it matters: Discovering new methods of making CRISPR's gene editing more precise are key to its future success in modifying crops and treating diseases. But, there's also a race among institutions — especially between UC and the Broad Institute — to own CRISPR patents that are potentially worth billions, per Reuters.

Show less

Background: CRISPR can use different enzymes, most often Cas9, to target specific genes for editing, but there remain safety concerns, as it's been shown to sometimes cause unwanted deletions, edit the wrong genes or move genes around. Guide RNAs can be used to locate the proper DNA sequence that needs to be cut.

By the numbers: This is UC Berkeley's third CRISPR patent and they expect a fourth to be issued soon.

READ MORE …

or go even deeper: UC Berkeley team awarded second CRISPR-Cas9 patent

Lucence improving personalized liver cancer treatment with AI

Lucence Diagnostics to Develop AI Tools for Liver Cancer Treatment

neo-urban-1734494_1280.jpg

Lucence Diagnostics, a genomic medicine company focused on personalizing cancer care, today announced a new project to develop AI algorithms for improving diagnosis and treatment of liver cancer. The goal is to combine the imaging and molecular data from liver cancer patients into smarter software tools that help physicians make better treatment decisions.

Lucence will be working with Olivier Gevaert, PhD, Assistant Professor of Medicine (Biomedical Informatics) and of Biomedical Data Science at the Stanford University School of Medicine. Having developed LiquidHALLMARK®, the world's first liquid biopsy next-generation sequencing test that analyzes the DNA of cancer-causing mutations and viruses, Lucence will contribute its genomics expertise and proprietary sequencing technology to this project.


READ MORE …

50,000 Human Exomes at the UK Biobank

New genetic data on 50,000 UK Biobank participants made available to the global health research community

A vast tranche of new UK Biobank genetic data becomes available to health researchers today, offering an unprecedented resource to enhance understanding of human biology and aid in therapeutic discovery.

The exome sequence data of 50,000 UK Biobank participants were generated at the Regeneron Genetics Center through a collaboration between UK Biobank, Regeneron (US) and GSK (UK) and are linked to detailed health records, imaging and other health-related data. Regeneron is also leading a consortium of biopharma companies (including Abbvie, Alnylam, AstraZeneca, Bristol-Myers Squibb, Biogen, Pfizer and Takeda) to complete exome sequencing of the remaining 450,000 UK Biobank participants by 2020. In addition, GSK has committed a £40 million investment to initiatives, such as UK Biobank, that harness advances in genetic research in the development of new medicines

READ MORE …

EU Genomics sector has some reliable bets

10 European Genomics Companies to Watch Out For

European Genomics Companies. Genome Media.

Next generation sequencing has revolutionized the biotech industry and genomics technology has changed dramatically over the last few years. There are many interesting European genomics companies, but here are 10 we thought especially worthy of mention.


READ MORE …

Big players dominate global Liver Cancer diagnostics for foreseeable future

Big players dominate global Liver Cancer diagnostics. Genome Media.

The Global Liver Cancer Diagnostic Market to 2025 - Leading Players are Illumina, Qiagen, F. Hoffmann-La Roche, Siemens Healthcare, and Thermo Fisher Scientific

Dublin, March 08, 2019 (GLOBE NEWSWIRE) -- The "Liver Cancer Diagnostic Market Size, Share & Trends Analysis Report By Screening Type (Biopsy, Endoscopy, Laboratory Tests, Imaging), By Region (North America, APAC, Europe), And Segment Forecasts, 2019 - 2025"report has been added to ResearchAndMarkets.com's offering.

The global liver cancer diagnostics market size is expected to reach USD 15.4 billion by 2025. The market is projected to expand at a CAGR of 8.1% over the estimated time period.

Rise in disease incidence coupled with growing demand for novel diagnosis products are thrusting the growth of the market. Hepatocellular Carcinoma (HCC) is the most common type of primary liver cancer in adults. It is among the common causes of death in people with liver cirrhosis and the third-leading cause of cancer deaths across the globe. Poor survival rate and lack of therapies has made this disease a crucial health issue worldwide.


READ LINK …

Increasing CRISPR efficiency, and specificity with zinc-finger proteins (original article)

Diversifying the structure of zinc finger nucleases for high-precision genome editing

Increasing CRISPR efficiency, and specificity with zinc-finger proteins. Genome Media.

Abstract—Genome editing for therapeutic applications often requires cleavage within a narrow sequence window. Here, to enable such high-precision targeting with zinc-finger nucleases (ZFNs), we have developed an expanded set of architectures that collectively increase the configurational options available for design by a factor of 64. These new architectures feature the functional attachment of the FokI cleavage domain to the amino terminus of one or both zinc-finger proteins (ZFPs) in the ZFN dimer, as well as the option to skip bases between the target triplets of otherwise adjacent fingers in each zinc-finger array. Using our new architectures, we demonstrate targeting of an arbitrarily chosen 28 bp genomic locus at a density that approaches 1.0 (i.e., efficient ZFNs available for targeting almost every base step). We show that these new architectures may be used for targeting three loci of therapeutic significance with a high degree of precision, efficiency, and specificity.


READ MORE …

3 Technologies That Could Create Trillion-Dollar Markets Over the Next Decade

Go back to the typical household in 1950, and you would see much that you would recognize: washing machines, vacuum cleaners, cars, TVs. But go back 50 years earlier, to 1900, and most of us would find a world that was utterly foreign, and exhausting. Daily chores like cooking and washing took hours of backbreaking labor. That’s because in the early 20th century, electricity and internal combustion completely changed how we live, transforming our cities, our homes, how we shop, eat, work, and just about every other facet of daily existence.

We’re on the cusp of a similar point today, except it is not just two technologies that are poised to change the world, but three of them: gene editing, new computing architectures, and materials science are just beginning to make the leap from lab to market. Taken together, these could be as transformative as electricity and internal combustion, which kicked off a 50-year productivity boom.

READ MORE…